<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhang Y</submitter><funding>National Administration of Traditional Chinese Medicine</funding><funding>Tianjin Municipal Science and Technology Bureau</funding><funding>National Natural Science Foundation of China</funding><pagination>e2104463</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9218761</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(18)</volume><pubmed_abstract>Characterized by an excessively increased uric acid (UA) level in serum, hyperuricemia induces gout and also poses a great threat to renal and cardiovascular systems. It is urgent and meaningful to perform early warning by noninvasive diagnosis, thus conducing to blockage of disease aggravation. Here, guanidinocalix[5]arene (GC5A) is successfully identified from the self-built macrocyclic library to specifically monitor UA from urine by the indicator displacement assay. UA is strongly bound to GC5A at micromolar-level, while simultaneously excluding fluorescein (Fl) from the GC5A·Fl complex in the "switch-on" mode. This method successfully differentiates patients with hyperuricemia from volunteers except for those with kidney dysfunction and targets a volunteer at high risk of hyperuricemia. In order to meet the trend from hospital-centered to individual-centered testing, visual detection of UA is studied through a smartphone equipped with a color-scanning feature, whose adaptability and feasibility are demonstrated in sensing UA from authentic urine, leading to a promising method in family-centered healthcare style. A high-throughput and visual detection method is provided here for alarming hyperuricemic by noninvasive diagnosis.</pubmed_abstract><journal>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</journal><pubmed_title>Noninvasive and Individual-Centered Monitoring of Uric Acid for Precaution of Hyperuricemia via Optical Supramolecular Sensing.</pubmed_title><pmcid>PMC9218761</pmcid><funding_grant_id>20ZYJDJC00070</funding_grant_id><funding_grant_id>ZYYCXTD-D-202002</funding_grant_id><funding_grant_id>81873192</funding_grant_id><pubmed_authors>Geng WC</pubmed_authors><pubmed_authors>Guo DS</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Yue YX</pubmed_authors><pubmed_authors>Chai S</pubmed_authors><pubmed_authors>Li JJ</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Yu H</pubmed_authors><pubmed_authors>Chai X</pubmed_authors><pubmed_authors>Wang L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Noninvasive and Individual-Centered Monitoring of Uric Acid for Precaution of Hyperuricemia via Optical Supramolecular Sensing.</name><description>Characterized by an excessively increased uric acid (UA) level in serum, hyperuricemia induces gout and also poses a great threat to renal and cardiovascular systems. It is urgent and meaningful to perform early warning by noninvasive diagnosis, thus conducing to blockage of disease aggravation. Here, guanidinocalix[5]arene (GC5A) is successfully identified from the self-built macrocyclic library to specifically monitor UA from urine by the indicator displacement assay. UA is strongly bound to GC5A at micromolar-level, while simultaneously excluding fluorescein (Fl) from the GC5A·Fl complex in the "switch-on" mode. This method successfully differentiates patients with hyperuricemia from volunteers except for those with kidney dysfunction and targets a volunteer at high risk of hyperuricemia. In order to meet the trend from hospital-centered to individual-centered testing, visual detection of UA is studied through a smartphone equipped with a color-scanning feature, whose adaptability and feasibility are demonstrated in sensing UA from authentic urine, leading to a promising method in family-centered healthcare style. A high-throughput and visual detection method is provided here for alarming hyperuricemic by noninvasive diagnosis.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jun</publication><modification>2024-02-15T22:34:17.401Z</modification><creation>2022-07-11T05:24:15.327Z</creation></dates><accession>S-EPMC9218761</accession><cross_references><pubmed>35484718</pubmed><doi>10.1002/advs.202104463</doi></cross_references></HashMap>